Comorbid conditions such as type 2 diabetes, hypertension, or sleep apnea may require indefinite GLP-1 continuation for cardiovascular and metabolic protection independent of weight loss goals
GLP-1 medications reduce appetite sometimes dramatically
In the UK, there are specific NHS criteria: Semaglutide 2.4mg (Wegovy) : NICE technology appraisal TA875 recommends this only within specialist weight management services and for a maximum of 2 years on the NHS [2] Liraglutide 3.0mg (Saxenda) : NICE technology appraisal TA664 specifies that treatment should only continue beyond 12 weeks if you've lost at least 5% of your initial body weight Clinical trials have demonstrated that most people regain weight after stopping GLP-1 medications
How Gard Wellness Can Help You with Peptide Therapy At Gard Wellness, were committed to helping our patients achieve lasting weight loss using cutting-edge treatments like peptide therapy
S2CID 44318394
Looker KJ, Magaret AS, Turner KM, Vickerman P, Gottlieb SL, Newman LM